Posted on 1/15/19
Here's How Pfizer Gained 20.5% in 2018
What happenedShares of Pfizer (NYSE:PFE) gained 20.5% in 2018, according to data from S&P Global Market Intelligence, while its industry was getting hammered. The iShares U.S. . . .
Posted on 1/15/19
ORHub Announces New Contract with Metropolitan Surgery Center in New Jersey
ORHub, Inc. (OTC: ORHB), a SaaS-based healthcare data analytics company focused on the business of surgery to improve the profitability of hospitals, ambulatory surgery centers (ASCs) . . .
Posted on 1/15/19
Cancer Genetics Closes Public Offering of Common Stock
RUTHERFORD, N.J., Jan. 14, 2019 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq: CGIX), a leader in enabling precision medicine for immuno-oncology and genomic medicine through molecular . . .
Posted on 1/14/19
Bristol-Myers: Fattening Up The Pipeline With Celgene
Summary Bristol-Myers' $74bn deal for Celgene should be a net positive. Deal creates the #1 oncology franchise. Management is guiding to some lofty post-deal, synergy targets. . . .
Posted on 1/14/19
Here's Why Merck & Co. Surged 35.8% in 2018
What happenedShares of Merck & Co. (NYSE:MRK), a big pharmaceutical company, climbed 35.8% in 2018, according to data from S&P Global Market Intelligence. Continued success with . . .
Posted on 1/11/19
Cancer Genetics Prices Public Offering of Common Stock
RUTHERFORD, N.J., Jan. 09, 2019 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq: CGIX), a leader in enabling precision medicine for immuno-oncology and genomic medicine through molecular . . .
Posted on 1/11/19
Thomas Jefferson University and Temple University Enter Exclusive Negotiations
Two of Philadelphia's leading academic and healthcare organizations have signed an agreement that creates an exclusive 90-day window within which to consider and negotiate the acquisition . . .
Posted on 1/10/19
Why Johnson & Johnson Stock Fell 12% in December
What happened Johnson & Johnson (NYSE:JNJ) shares trailed the market last month as the stock lost 12% compared to a 9% slump in the S&P 500, . . .
Posted on 1/10/19
Group K Diagnostics Starts 2019 in New Center City Digs
Group K Diagnostics, the diagnostics startup that raised a $2-million Series A in November, is
Posted on 1/9/19
ANSYS Announces Winners of 2019 Hall of Fame Competition
From optimizing prosthetic foot designs to fighting heart disease to securing high voltage cables, the winning entries of the annual ANSYS (NASDAQ: ANSS) Hall of Fame . . .
Posted on 1/9/19
BioHiTech and Sprouts Partner
BioHiTech Global, Inc. (NASDAQ: BHTG), a technology and services company that provides cost-effective and sustainable waste management solutions, today announced the installation of BioHiTech Revolution Series Digester . . .
Posted on 1/9/19
FierceHealthcare Awards Hoy Health as one of its 2019 “Fierce 15” Companies, Recognizing its Innovative Healthcare Solutions
MORRISTOWN, N.J.--(BUSINESS WIRE)--Hoy Health, LLC announces that it has been named by FierceHealthcare as one of the 2019 Fierce 15 companies, designating it as one of . . .
Posted on 1/9/19
3 Things Bristol-Myers Squibb Understands About Celgene That the Market Hasn't
Healthcare's biggest event of the year is now under way -- the J.P. Morgan Healthcare Conference. Over the past several years, Celgene (NASDAQ:CELG) has traditionally kicked . . .
Posted on 1/8/19
Johnson & Johnson Innovation to Join NXT Biomedical Therapeutic Device Incubator to Accelerate Medical Device Innovation
Johnson & Johnson Innovation, LLC today announced it entered a definitive agreement to join NXT Biomedical Therapeutic Device Incubator through a strategic investment facilitated by Johnson . . .
Posted on 1/8/19
Merck & Co., Inc. (MRK) at JPMorgan Healthcare Conference (Transcript)
Earning Call Audio Start Time: 19:30 January 1, 0000 7:55 PM ET Merck & Co., Inc. (NYSE:MRK) JPMorgan Healthcare Conference January 07, 2019, 19:30 PM ET . . .
Posted on 1/8/19
3 Things Pfizer's New CEO Just Said That Investors Will be Glad to Hear
For the first time in eight years, a new Pfizer (NYSE:PFE) CEO took the stage at the J.P. Morgan Healthcare Conference. Albert Bourla took the reins . . .
Posted on 1/8/19
Bristol-Myers/Celgene: Win-Win Merger
Summary Bristol-Myers agreed to pay a 54% premium to acquire Celgene. Celgene shareholders get an immediate price boost plus the long-term potential to participate in cheap . . .
Posted on 1/8/19
Should Investors Like Bristol-Myers' Buyout of Celgene?
The first big merger of the year has arrived, in the form of a deal for Bristol-Myers Squibb (NYSE:BMY) to swallow Celgene (NASDAQ:CELG). The two are . . .
Posted on 1/8/19
3 Things Bristol-Myers Squibb Understands About Celgene That the Market Hasn't
Healthcare's biggest event of the year is now under way -- the J.P. Morgan Healthcare Conference. Over the past several years, Celgene (NASDAQ:CELG) has traditionally kicked . . .
Posted on 1/7/19
AM Best Ranks UnitedHealth Group and Allianz as World’s Largest Insurers
OLDWICK, N.J.--(BUSINESS WIRE)--UnitedHealth Group Incorporated occupied the top spot in AM Best’s ranking of the world’s 25 largest insurance companies for a fourth straight year, with . . .
Posted on 1/7/19
Tabula Rasa HealthCare Completes Acquisition of DoseMe
Tabula Rasa HealthCare, Inc. (TRHC) (NASDAQ: TRHC), a healthcare technology company advancing the field of medication safety, today announced that it completed its acquisition
Posted on 1/7/19
Celgene Corporation Announces 2019 Financial Guidance and Key Milestones
SUMMIT, N.J.--(BUSINESS WIRE)--Celgene Corporation (NASDAQ: CELG) today provides a business update, including confirmation that the company achieved its guidance for full-year 2018; its financial guidance for . . .
Posted on 1/7/19
Catalent Invests $200 Million to Expand Biologics Capacity and Capabilities
Catalent, Inc. (NYSE:CTLT), the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products
Posted on 1/7/19
Celgene: Still Upside Left After Deal?
Summary Yesterday, Bristol-Myers Squibb announced a deal to acquire Celgene. This was biggest deal in the biotech sector in many, many years. While Celgene has rallied . . .
Posted on 1/7/19
Merck Could Continue Gains As A Defensive Pick, With Growth On Top Of That
Summary Merck has been one of the best-performing large caps since volatility returned in October. I argue this is the results of prudent strategy and wise . . .

